{
    "clinical_study": {
        "@rank": "43375", 
        "arm_group": [
            {
                "arm_group_label": "Lot A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lot B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lot C", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lot D", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetics (the exposure of the trial drug in the body) of four lots of turoctocog\n      alfa (a human recombinant coagulation factor VIII (FVIII)) in subjects with haemophilia A."
        }, 
        "brief_title": "Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia A"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities. Trial-related\n             activities are any procedures that are carried out as part of the trial, including\n             activities to determine suitability for the trial\n\n          -  Male subjects with the diagnosis of severe haemophilia A (FVIII<1%) from age 18 years\n\n          -  Documented history of at least 150 exposure days to any other FVIII products\n             (prevention or treatment of bleeds)\n\n          -  Immunocompetent (HIV (Human Immunodeficiency Virus) positive subjects should have\n             CD4+ (Cluster of differentiation 4; a glycoprotein expressed on the surface)\n             lymphocyte count >200/microL)\n\n        Exclusion Criteria:\n\n          -  Detectable inhibitors to FVIII (above or equal to 0.6 Bethesda Units (BU))\n\n          -  History of FVIII inhibitors\n\n          -  Severe current hepatic dysfunction or severe hepatic disease during the last 12\n             months\n\n          -  Known or suspected allergy to trial product (FVIII) or related products\n\n          -  Subjects receiving immune modulating medication or immune tolerance induction (ITI)\n             regimens\n\n          -  Body mass index(BMI)  above 30 kg/m^2"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692925", 
            "org_study_id": "NN7008-4015", 
            "secondary_id": [
                "2012-001444-21", 
                "U1111-1129-1517"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lot A", 
                    "Lot B", 
                    "Lot C"
                ], 
                "description": "Trial product will be administered as an i.v. (intravenous) bolus injection. Each subject will receive two single doses of turocotocog alfa from two lots of trial product.", 
                "intervention_name": "turoctocog alfa 2000 IU/vial", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lot D", 
                "description": "Trial product will be administered as an i.v. (intravenous) bolus injection. Each subject will receive two single doses of turocotocog alfa from two lots of trial product.", 
                "intervention_name": "turoctocog alfa 3000 IU/vial", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 11, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10249"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia", 
                        "zip": "1006"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Latvia", 
                "Spain"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Multi-centre, Open-labelled Trial Investigating the Pharmacokinetics of Four Lots of Turoctocog Alfa in Subjects With Haemophilia A", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Judi M\u00f8ss", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Latvia: Ministry of Health", 
                "Spain: Spanish Agency of Medicines and Health Care Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Dose normalised area under the curve (AUC/actual dose) based on chromogenic assay", 
            "safety_issue": "No", 
            "time_frame": "up to 48 hours after i.v. administration"
        }, 
        "removed_countries": {
            "country": "Malaysia"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692925"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dose normalised area under the FVIII activity-time curve (AUC/actual dose) based on one stage clot assay", 
                "safety_issue": "No", 
                "time_frame": "up to 48 hours after i.v. administration"
            }, 
            {
                "measure": "Incremental recovery (IR30min) (defined as the peak FVIII level recorded 30 min after injection and reported as[IU/mL]/[IU/kg])", 
                "safety_issue": "No", 
                "time_frame": "up to 48 hours after i.v. administration"
            }, 
            {
                "measure": "Area under the FVIII activity-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "up to 48 hours after i.v. administration"
            }, 
            {
                "measure": "Terminal half-life of FVIII (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "up to 48 hours after i.v. administration"
            }, 
            {
                "measure": "Clearance of FVIII (CL)", 
                "safety_issue": "No", 
                "time_frame": "up to 48 hours after i.v. administration"
            }, 
            {
                "measure": "Incidence of adverse events (AEs) including FVIII inhibitors", 
                "safety_issue": "No", 
                "time_frame": "After approximately 3 months (at end of trial)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}